EOSINOPHIL-DEFICIENT TRANSGENIC ANIMALS

摘要

The technologies described herein are based on the discovery that expression of a toxin gene under control of an eosinophil-specific promoter can cause the ablation of eosinophils in a transgenic animal. Accordingly, the nucleic acid constructs featured in the invention are used to generate eosinophil-deficient transgenic animals that are useful for the study of pathologies and treatments relating to tissues and organ systems that typically contain eosinophils.